Trusted relationships, quality service, outcome oriented approach
Xelium advises clients in the areas of Strategy, Business Development and Mergers and Acquisitions.
Xelium is deeply routed in the Life Science and adjacent industry sectors such as Chemicals and Renewables. We offer access to a global network of industry experts and investors in Asia, US and Europe.
Combining Life Science education with a deep sector understanding, we believe that our advisory approach offers exceptional value and insights for clients, driving corporate development, strategic growth and innovation in a dynamic environment.
Our clients are ranging from start-ups, corporates, family offices to financial investors in the sector.
Our advisory solutions are independent and building on trusted relationships, dedication, pragmatism, efficiency, strong execution skills, value and quality of services delivered to our clients.
Our team structure is flexible and tailored to the client needs with the goal to deliver high quality solutions in an efficient manner. We emphasize trust, partnership and transparency with our clients and the team.
Ulf Hoppmann – Managing Director
15 years’ experience covering positions in Strategy, Business Development, Mergers & Acquisitions at EY, Boehringer Ingelheim, Lianhetech and Heraeus.
Over 30 transactions of various deal types: Acquisitions, licensing deals, equity investments, manufacturing site divestitures, product portfolio divestitures and corporate restructurings.
International experience and a global network in Life Science having worked and lived in Germany, UK, Singapore, China and Australia.
Degree in Technical Chemistry and Business from the Technical University Berlin, Germany and Master of International Business from the Macquarie University, Sydney.
UK based support team with research analysts and consultants.
Xelium works with clients to design and implement strategic planning on corporate, business and functional level.
Leveraging our expertise in Life Science we help clients to develop a business plan tailored to the needs of certain stakeholders such as employees, management, board and investors.
Identifying growth opportunities beyond an existing, well established business portfolio or commercialisation of new technologies requires an outside-in view and perhaps new relationships to customers and industry stakeholders. Assessment of technologies, business models, and market potential is supported by quantitative and qualitative market research.
Corporate divestment decisions are caused by succession planning, change of strategic direction and exit considerations of financial investors.
Based on a trusted and sensible relationship with our clients we support navigating the deal life cycle from strategic option development, valuation considerations, due diligence management to negotiation of transaction contracts.
We help clients to raise growth capital in close collaboration with strategic, institutional and financial investors.
Xelium supports the evaluation process of new business areas in terms of commercial feasibility studies and market attractiveness assessment, facilitated by approaching new customers with regards to potential business opportunities.
Xelium is available to help with certain aspects, consisting of portfolio analysis, due diligence management, project management, company/product valuation, negotiation support, market entry support, sector and peer group analysis.
Based on the fluctuating client needs and capacity constraints we support with interim management.
With non-executive board representations we are helping clients with relationships, network and expertise in M&A and Business Development.
Accelerating business growth, expansion in adjacent technologies and markets, are predominantly driving the desire for product, technology and company acquisitions.
Leveraging our market, technical and commercial knowledge we engage with clients to develop a tailored external growth strategy, acquisition candidate screening, profiling, approach and support of the transaction process.
Angaben gemäß § 5 TMG / § 55 RStV
61118 Bad Vilbel
Registered company name: Xelium GmbH
Commercial register entry: HRB 123206
Verantwortlich für den Inhalt
nach § 55 Abs. 2 RStV
Search of a global licensing partner for a midsize US based specialty pharma business.
Identification of potential acquisition opportunities for a biopharmaceutical CDMO and supplier in new markets such as Cell and Gene Therapy.
Divestment of three manufacturing sites in drug product and drug substance for a multinational pharmaceutical company.
Acquisition of a Fine Chemical Business based in the UK by a listed company from China.
Strategic initiatives leading to the identification of potential acquisition targets in pharma, biotech, renewables, performance chemicals.
Initiation and execution of commercial collaborations in Fuel Cells and Electrolysis for a multinational chemical company.
Divestment of 70% joint venture equity share for a multinational performance chemical company in China.
Acquisition of a biopharmaceutical manufacturing site based in the US.
Strategic licensing collaboration combined with equity investment between a multinational pharmaceutical company and a biotech start-up.
Joint venture between a biotech start-up and mid-size pharmaceutical company in biomolecule purification.